{"filing":{"accession_number":"0001818794-26-000003","cik":"0001818794","ticker":"DYN","company_name":"Dyne Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-17","report_date":null,"primary_document":"dyn-20260616.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1818794/000181879426000003/dyn-20260616.htm"},"events":[{"id":11443,"run_id":10046,"accession_number":"0001818794-26-000003","anchor_item_number":"1.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Dyne Therapeutics entered into a Second Amendment to its Loan and Security Agreement, expanding the debt facility from prior levels to an aggregate of $400.0 million through the addition of two new $50.0 million tranches and a $25.0 million increase to the final tranche, with an immediate $50.0 million borrowing. This material financing event expands the company's credit capacity by $125.0 million and affects its capital structure and liquidity position.","company_name":"Dyne Therapeutics, Inc.","ticker":"DYN","filing_date":"2026-06-17","form":"8-K","submitted_at":null,"items":[{"id":8033,"accession_number":"0001818794-26-000003","item_number":"1.01","item_title":"Entry Into a Material Definitive Agreement.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure describes entry into a Second Amendment to a Loan and Security Agreement that materially expands the debt facility from prior levels to an aggregate of $400.0 million, adds two new $50.0 million tranches, increases the final tranche by $25.0 million, and results in an immediate $50.0 million borrowing. While this is a debt financing rather than a traditional M\u0026A transaction, Item 1.01 encompasses \"Entry Into a Material Definitive Agreement,\" and the expansion of a credit facility by $125.0 million in new capacity with immediate drawdown is a material financing event affecting the company's capital structure and liquidity position.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-17T11:36:09.731531+00:00","company_name":"","ticker":null,"filing_date":""},{"id":8034,"accession_number":"0001818794-26-000003","item_number":"2.03","item_title":"Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.45,"reasoning":"Item 2.03 discloses creation of a direct financial obligation, but the section provided contains only a cross-reference to Item 1.01 without substantive detail. Item 1.01 typically covers material acquisitions or dispositions. Without the actual Item 1.01 content, the specific nature of the obligation cannot be determined; however, Item 2.03 filings are generally material to investors as they signal new debt or financial commitments. Classified as other_material due to insufficient detail in the provided text.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-17T11:36:09.731531+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":8033,"accession_number":"0001818794-26-000003","item_number":"1.01","item_title":"Entry Into a Material Definitive Agreement.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure describes entry into a Second Amendment to a Loan and Security Agreement that materially expands the debt facility from prior levels to an aggregate of $400.0 million, adds two new $50.0 million tranches, increases the final tranche by $25.0 million, and results in an immediate $50.0 million borrowing. While this is a debt financing rather than a traditional M\u0026A transaction, Item 1.01 encompasses \"Entry Into a Material Definitive Agreement,\" and the expansion of a credit facility by $125.0 million in new capacity with immediate drawdown is a material financing event affecting the company's capital structure and liquidity position.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-17T11:36:09.731531+00:00","company_name":"Dyne Therapeutics, Inc.","ticker":"DYN","filing_date":"2026-06-17"},{"id":8034,"accession_number":"0001818794-26-000003","item_number":"2.03","item_title":"Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.45,"reasoning":"Item 2.03 discloses creation of a direct financial obligation, but the section provided contains only a cross-reference to Item 1.01 without substantive detail. Item 1.01 typically covers material acquisitions or dispositions. Without the actual Item 1.01 content, the specific nature of the obligation cannot be determined; however, Item 2.03 filings are generally material to investors as they signal new debt or financial commitments. Classified as other_material due to insufficient detail in the provided text.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-17T11:36:09.731531+00:00","company_name":"Dyne Therapeutics, Inc.","ticker":"DYN","filing_date":"2026-06-17"}]}